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Background 
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder of vascular 
dysplasias that is characterized by mucocutaneous telangiectasias, gastrointestinal tract bleeding, 
and arteriovenous malformations (AVMs) of the pulmonary, hepatic, and cerebral vascular systems. 
 
Case Summary 
A seven-year-old boy presented to his primary care provider with a five-day history of watery 
diarrhea and was incidentally found to have oxygen saturations in the low eighties, perioral 
cyanosis, and clubbing on physical exam. He was referred to the pediatric emergency department 
(ED) for evaluation. Upon presentation to the pediatric ED, oxygen saturation ranged from 74-85%. 
He was in no acute distress and was afebrile with normal vital signs. The patient was small for his 
age with height and weight in the thirteenth and third percentiles, respectively, and had central 
cyanosis and clubbing of fingers and toes. Auscultation revealed diminished lung sounds in the 
right lower lobe. No mucocutaneous telangiectasias or cardiac murmurs were appreciated. Family 
history was positive for hereditary hemorrhagic telangiectasia (HHT) with gastrointestinal bleeding 
and anemia in his maternal great grandmother and maternal grandmother, minor bleeding and 
mucocutaneous telangiectasias in his mother, and cyanosis with exercise and recurrent epistaxis in 
his brother. 
 
Complete blood count was significant for a hemoglobin level of 18.1 g/dL. A chest x-ray (Figure 1) 
showed an airspace opacification within the superior segment of the right lower lobe suspicious for 
an arteriovenous malformation (AVM). 
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Figure 1. Chest x-ray during initial evaluation demonstrating airspace opacification (arrows) 
within the superior segment of the right lower lobe. 
 
 
 
 
 
 
An echocardiogram with bubble study was performed at the bedside in the ED and was positive 
with a large volume of bubbles in the left heart, consistent with a right-to-left shunt (Figure 2).  
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Video 1. Echocardiography conducted at the bedside with positive bubble study, confirming a 
right-to-left shunt. 
 
 
A chest CT demonstrated clusters of round opacities in the right lower lobe with a large feeding 
artery originating from the right interlobar artery and an enlarged left lower pulmonary vein, 
consistent with a dominant AVM (Figures 3 & 4).  
 
Figure 3. Anterior thoracic computed tomography scan illustrating a dominant pulmonary 
arteriovenous malformation (solid arrows) in the right lower lung lobe. There is a large feeder 
vessel (open arrows), and the right lower pulmonary vein is dilated (asterisk). 
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Figure 4. Posterior thoracic computed tomography scan illustrating a dominant pulmonary 
arteriovenous malformation (solid arrows) in the right lower lung lobe. There is a small 
feeder vessel (open arrows) which is more superior than the larger vessel seen in figure 2. 
 
 
 
The patient underwent percutaneous right heart catheterization. Angiography of the right pulmonary 
artery revealed an AVM with a large feeder vessel, approximately 7mm in diameter, and several 
smaller feeder vessels (figure 5).  
 
Figure 5. Angiography of the right pulmonary demonstrating a large arteriovenous 
malformation with multiple feeder vessels. 
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A 12mm plug was placed in the larger vessel and three 4mm plugs were placed in other feeder 
vessels, which can be seen post-embolization via angiogram (figure 6).  
Figure 6: Angiography of the right pulmonary artery post-embolization illustrating effective 
reduction of right-to-left shunt. 
 
 
A few smaller vessels that fed the AVM were identified but we decided not to occlude them due to 
their small size. Two hours post-procedure, the patient was awake and alert in bed. His oxygen 
saturation was 95%, and his digital and peri-oral cyanosis had resolved. At one-month follow-up, 
the patient was doing well; he remained acyanotic and his oxygen saturation was 90%. At future 
follow-up visits we will assess the need for additional embolization of the smaller feeder vessels 
noted on angiography post-embolization. The patient and his family were also encouraged to follow 
up with the hospital’s genetics service for further evaluation and potential screening for hepatic and 
brain AVMs. 
 
Discussion 
Hereditary hemorrhagic telangiectasia (HHT), or Osler-Weber-Rendu syndrome, is an autosomal 
dominant disease of vascular dysplasias, classically characterized by mucocutaneous telangiectasias 
and vascular malformations. The disease was initially described in the late 19th century as a familial 
disorder of cutaneous telangiectasias, recurrent epistaxis, and gastrointestinal bleeding,1-3 which are 
the most common presenting signs of the disease. HHT has since been understood to cause visceral 
arteriovenous malformations (AVMs) in the pulmonary, hepatic, and cerebral vascular system, as 
well4.  
 
HHT’s prevalence is estimated to be one in 5,000-10,000,4,5 with some reports suggesting an even 
higher frequency.6 Clinical manifestations of HHT depend on which of the above vascular 
dysplasias are present in an individual, and penetrance is age-related with complete penetrance 
generally manifesting by age 40.5 Frequent epistaxis, which is the most common complaint, begins 
at an average of 12 years of age,7 and mucocutaneous telangiectasias often present after the onset of 
epistaxis. Pulmonary AVMs are reported to occur in 40-60% of affected individuals,4,5 and they 
more commonly present in a younger population than hepatic or cerebral AVMs.8  
 
Diagnosis of HHT is commonly based on clinical manifestations and family history, but can now 
also be made based on genetic testing. The clinical diagnosis depends on four criteria as defined by 
the Curaçao Criteria:9 recurrent epistaxis, telangiectasias at characteristic sites (lips, oral cavity, 
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fingers, nose), visceral lesions identified via diagnostic imaging, and family history in a first-degree 
relative. Diagnosis of HHT is “definite” if three or more criteria are present and “suspected” if two 
criteria are present. Genetic testing is now also available, which allows for familial diagnosis and 
may aid in diagnosing relatives who do not yet meet clinical diagnostic criteria. All HHT cases with 
an identified genetic cause are believed to be due to mutations in transforming growth factor beta 
(TGF-) signaling. At least 85% of cases are caused by mutations in the endoglin gene (ENG) and 
activin-A receptor type II-like 1 gene (ACVRL1),6,10 and a small number of HHT cases have 
recently been attributed to mutations identified in the SMAD4 and GDF2 genes, as well.  
 
Screening for visceral involvement is recommended for all patients diagnosed with HHT due to the 
potentially devastating complications of pulmonary, cerebral, and hepatic AVMs.6 Pulmonary 
AVMs are most commonly confirmed via thoracic CT or transthoracic contrast echocardiography 
(TTCE) with bubble study, although a chest radiograph may be used as a first-line screening test 
due to its efficiency and low cost.5 In contrast, cerebral AVMs are often diagnosed via MRI to 
minimize brain radiation, and hepatic AVMs can be diagnosed by Doppler sonography, MRI, or 
CT.6 
 
Treatment of patients with HHT varies by individual features of the disease. Experts recommend 
that all pulmonary AVMs be treated due to the potential for development of cyanosis, stroke, heart 
failure, or pulmonary hemorrhagic complications.6 Percutaneous transcatheter embolization of 
pulmonary AVMs is now the most common method of treatment. Catheter based therapy is 
effective and less invasive than traditional surgical techniques.5 Similarly, cerebral AVMs are often 
treated via embolization and/or microsurgery and stereotactic radiation with high operational risk, 
and hepatic AVMs are treated via hepatic artery embolization or liver transplantation with variable 
results/effectiveness.6 
 
This case was unique because the patient presented with only signs of chronic cyanosis and no 
history of epistaxis, mucocutaneous telangiectasias, gastrointestinal bleeding, or iron-deficient 
anemia. However, given his family history of one or more of these symptoms for four consecutive 
generations, clinical suspicion was high that his cyanosis was due to a pulmonary AVM caused by 
underlying HHT. The presence of an AVM was screened for via chest x-ray and confirmed via 
TTCE and thoracic CT. The patient was treated via percutaneous catheterization and embolization 
of the largest feeder vessels with great clinical effect, as demonstrated by resolution of cyanosis. 
Overall, this case illustrates efficient diagnosis and treatment of a patient with suspected HHT who 
presented without the traditional signs of the disease. Given the patient’s young age he is at high 
risk of developing additional AVMs in the future,8 so close follow-up and monitoring is 
encouraged. 
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